We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The Real-World Outcome of First Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Multicenter Prospective Cohort Study.
- Authors
Choi, Myeong Geun; Kim, Yeon Joo; Lee, Jae Cheol; Ji, Wonjun; Oh, In-Jae; Lee, Sung Yong; Yoon, Seong Hoon; Lee, Shin Yup; Lee, Jeong Eun; Kim, Eun Young; Choi, Chang-Min
- Abstract
Purpose The addition of immune checkpoint inhibitors to chemotherapy has improved survival outcomes in patients with extensivestage small cell lung cancer (ES-SCLC). However, their real-world effectiveness remains unknown. Therefore, we investigated the effectiveness of atezolizumab plus chemotherapy in ES-SCLC in actual clinical settings. Materials and Methods In this multicenter prospective cohort study, patients with ES-SCLC receiving or scheduled to receive atezolizumab in combination with etoposide and carboplatin were enrolled between June 2021 and August 2022. The primary outcomes were progression-free survival (PFS) and the 1-year overall survival (OS) rate. Results A total of 100 patients with ES-SCLC were enrolled from seven centers. Median age was 69 years, and 6% had an Eastern Cooperative Oncology Group performance status (ECOG PS) = 2. The median PFS was 6.0 months, the 1-year OS rate was 62.2%, and the median OS was 13.5 months. An ECOG PS of 2-3 and progressive disease as the best response were poor prognostic factors for PFS, while an ECOG PS of 2-3 and brain metastasis were associated with poor prognosis for OS. In addition, consolidative thoracic radiotherapy was found to be an independent favorable prognostic factor for OS (hazard ratio, 0.336; p=0.021). Grade = 3 treatmentrelated adverse events were observed in 7% of patients, with treatment-related deaths occurring in 2% of patients. Conclusion We provided evidence of the favorable real-world effectiveness and safety of atezolizumab plus chemotherapy in ES-SCLC patients, including in the elderly and those with poor ECOG PS. Additional consolidative thoracic radiotherapy may also benefit ES-SCLC patients.
- Subjects
SMALL cell lung cancer; ATEZOLIZUMAB; IMMUNE checkpoint inhibitors; COHORT analysis; LONGITUDINAL method
- Publication
Cancer Research & Treatment, 2024, Vol 56, Issue 2, p422
- ISSN
1598-2998
- Publication type
Article
- DOI
10.4143/crt.2023.913